Shanghai Henlius Biotech, Inc. (HKG:2696)

Market Cap	33.23B +27.9%
Revenue (ttm)	7.42B +16.5%
Net Income	920.34M +0.8%
EPS	1.68 +0.0%
Shares Out	543.49M
PE Ratio	36.39
Forward PE	23.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,085,083
Open	63.25
Previous Close	63.60
Day's Range	60.65 - 64.60
52-Week Range	50.90 - 92.00
Beta	0.50
Analysts	Strong Buy
Price Target	102.28 (+67.47%)
Earnings Date	Aug 25, 2026

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,762
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2696

Financial Performance

In 2025, Shanghai Henlius Biotech's revenue was 6.67 billion, an increase of 16.46% compared to the previous year's 5.72 billion. Earnings were 827.04 million, an increase of 0.80%.

Financial numbers in CNY

Analyst Summary

According to 8 analysts, the average rating for 2696 stock is "Strong Buy." The 12-month stock price target is $102.28, which is an increase of 67.47% from the latest price.

Price Target

$102.28

(67.47% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 9, 2026

Data Sources Report a data error